-
CRISPR-Cas Antimicrobial Therapy: Evidence and Limits
2026-09-28
The 2025 review by Yang and colleagues frames CRISPR-Cas as a programmable antimicrobial strategy for selectively eliminating pathogens, removing antibiotic-resistance genes, and engineering bacteriophages. Its main practical contribution is an integrated analysis of CRISPR mechanisms, delivery vehicles, phage applications, and the biological barriers that still separate promising laboratory concepts from deployable therapies.
-
TSA Beyond Tumor Cells: Epigenetics Meets Immunity
2026-09-28
Trichostatin A (TSA) is best understood not simply as a way to alter histone acetylation, but as a context-dependent probe of cell state. This article connects its established cancer-research applications with findings in stressed dendritic cells, then translates those insights into practical experimental choices—while keeping preclinical promise distinct from clinical evidence.
-
SIRT1/2 Inhibitor IV: Practical Research Workflows
2026-09-27
Use SIRT1/2 Inhibitor IV (cambinol) to test how sirtuin activity intersects with lactate signaling, protein modification, and cell phenotype. The guide pairs an emerging astrocyte OGD/R application with established cancer-model observations, while highlighting controls needed to interpret a dual, high-micromolar inhibitor.
-
Belinostat (PXD101): In Vitro Assay Workflow
2026-09-26
Use Belinostat (PXD101) to probe how pan-HDAC inhibition changes histone acetylation, proliferation, cell-cycle distribution, and cell killing in cancer models. A paired-readout workflow helps distinguish growth arrest from loss of viable cells—two drug responses that a single endpoint can blur.
-
BCL-2 Targeting Across Heterogeneous CRPC
2026-09-25
Single-cell imaging and preclinical models show that BCL-2-positive prostate cancer cells increase in castration-resistant disease, including cells with different androgen-receptor states. The study links AR inhibition to BCL-2 derepression and provides early clinical evidence that combining enzalutamide with venetoclax may reduce circulating tumor cells in some patients.
-
3X (DYKDDDDK) Peptide for Protein Workflows
2026-09-25
Use the 3X (DYKDDDDK) Peptide as a soluble competitor to help release FLAG-tagged proteins from affinity matrices and support clean downstream analysis. This workflow-focused guide connects tag-based protein handling to kinase-substrate research while flagging the controls needed for phosphorylation and metal-sensitive assays.
-
ATRX Loss and the Translational Case for RTK Inhibition
2026-09-24
ATRX deficiency may help explain why some high-grade glioma cells respond differently to receptor tyrosine kinase and PDGFR inhibitors. This article examines the mechanistic rationale, experimental considerations, and clinical-trial implications—and offers a cautious framework for evaluating AZ 10417808 without assuming an unverified target or study role.
-
Cecal Omics After E. tenella Treatment in Chickens
2026-09-24
This study paired 16S rRNA gene sequencing with LC-MS/MS metabolomics to examine how Eimeria tenella infection and treatment reshape the chicken cecal environment. Ethanamizuril was associated with a microbiota profile interpreted as more stable, while sulfachlorpyridazine was associated with lower Escherichia-Shigella; the low-dose combination had limited effects under the conditions tested.
-
DCFH-DA Workflows for Cellular ROS Assays
2026-09-23
Use DCFH-DA to compare intracellular oxidative activity across microscopy, flow cytometry, and plate-reader workflows—not to identify a specific ROS or its source. A granulosa-cell study of LSKL and THBS1 offers a practical disease-model example, with controls and optimization tips for making fluorescence results more interpretable.
-
M344: From Chromatin Control to Cancer Assays
2026-09-23
M344 is a cell-permeable histone deacetylase inhibitor that links chromatin remodeling to cell-cycle arrest, apoptosis, differentiation, and tumor control. This evidence-driven guide explains how to select assays, interpret exposure, and translate neuroblastoma findings into rigorous cancer research workflows.
-
Dual HER2–VEGFR-2 Targeting in Breast Cancer
2026-09-22
A 2026 study examined Lapatinib and Telatinib in HER2-negative MDA-MB-231 triple-negative breast cancer cells, showing reduced proliferation, invadopodia formation, and two-dimensional tube formation. The work supports phenotype-first targeted cancer therapy research while leaving direct receptor engagement and formal combination synergy unresolved.
-
PFHxS Hepatotoxicity via PPAR Signaling in Zebrafish
2026-09-22
The reference study shows that environmentally relevant exposure to perfluorohexanesulfonic acid (PFHxS) can damage developing zebrafish liver through a PPAR-associated mechanism. Its main advance is the combination of transcriptomics, pathology, biochemical measurements, targeted gene analysis, pharmacological antagonism, and PPAR morpholino knockdown to connect pathway enrichment with observable hepatotoxicity.
-
SIRT1/2 Inhibitor IV: A Mechanism-First Guide
2026-09-21
SIRT1/2 Inhibitor IV (cambinol) provides a cell-permeable way to interrogate SIRT1/2-dependent acetylation, metabolism, and tumor biology. This guide connects biochemical validation with lactylation, astrocyte, p53, and xenograft assay decisions while clearly separating evidence from testable hypotheses.
-
SIRT1, Type H Vessels, and Aging Bone Repair
2026-09-21
Liu et al. show that SIRT1 coordinates endothelial activity and osteogenic differentiation in aged bone models, with β-catenin deacetylation and nuclear translocation implicated as a mechanistic link to Wnt signaling. The study connects vascular–skeletal dysfunction with impaired regeneration and supports SIRT1 activation as a research strategy for age-related bone repair, while leaving important translational questions unresolved.
-
Tubastatin A Protects the Heart After Cardiac Arrest
2026-09-20
A 2025 porcine study reports that Tubastatin A reduced myocardial dysfunction and injury after cardiac arrest and resuscitation, with effects associated with lower GSDME-related pyroptosis and MLKL-related necroptosis. The findings extend HDAC6 inhibitor research into a clinically relevant large-animal model while emphasizing that pathway involvement, rather than definitive causality, remains to be established.